Smith & Nephew (SNN) Competitors

Zimmer Biomet (NYSE:ZBH) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Do analysts recommend ZBH or SNN?

Zimmer Biomet currently has a consensus price target of $123.33, suggesting a potential upside of 15.46%. Given Zimmer Biomet's higher possible upside, research analysts clearly believe Zimmer Biomet is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.25
Smith & Nephew	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Is ZBH or SNN more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Smith & Nephew's net margin of 0.00%. Zimmer Biomet's return on equity of 12.95% beat Smith & Nephew's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	14.27%	12.95%	7.55%
Smith & Nephew	N/A	N/A	N/A

Does the MarketBeat Community prefer ZBH or SNN?

Zimmer Biomet received 452 more outperform votes than Smith & Nephew when rated by MarketBeat users. Likewise, 67.16% of users gave Zimmer Biomet an outperform vote while only 54.43% of users gave Smith & Nephew an outperform vote.

Company	Underperform	Outperform
Zimmer Biomet	Outperform Votes 900 67.16%	Underperform Votes 440 32.84%
Smith & Nephew	Outperform Votes 448 54.43%	Underperform Votes 375 45.57%

Which has better earnings & valuation, ZBH or SNN?

Zimmer Biomet has higher revenue and earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.60B	2.80	$1.02B	$5.26	20.31
Smith & Nephew	$5.64B	1.90	$263M	$1.96	12.52

Is ZBH or SNN a better dividend stock?

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.9%. Smith & Nephew pays an annual dividend of $0.54 per share and has a dividend yield of 2.2%. Zimmer Biomet pays out 18.3% of its earnings in the form of a dividend. Smith & Nephew pays out 27.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Which has more volatility and risk, ZBH or SNN?

Zimmer Biomet has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Does the media refer more to ZBH or SNN?

In the previous week, Zimmer Biomet had 8 more articles in the media than Smith & Nephew. MarketBeat recorded 12 mentions for Zimmer Biomet and 4 mentions for Smith & Nephew. Zimmer Biomet's average media sentiment score of 0.67 beat Smith & Nephew's score of 0.44 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in ZBH or SNN?

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew shares are held by institutional investors. 0.7% of Zimmer Biomet shares are held by insiders. Comparatively, 1.0% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Zimmer Biomet beats Smith & Nephew on 17 of the 20 factors compared between the two stocks.